Progression of fibrosis in liver transplant recipients with hepatitis C before and after sustained virologic response
Clinical Transplantation · 2023
DOI: 10.1111/ctr.15050 ↗At a glance
Journal article in Clinical Transplantation, 2023. Written by Alex Liu and 6 co-authors. Institution: Division of Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA. Major MEDLINE topics: Liver Transplantation, Hepatitis C, Chronic, Hepatitis C. Cited 5 times so far (Crossref); 16 references.
Abstract (original language)
Background
Liver transplant (LT) recipients with untreated hepatitis C (HCV) are at risk for cirrhosis graft failure. The advent of direct acting antiviral agents (DAA) has improved outcomes in HCV.
Aims
We aim to examine liver transplant outcomes and allograft fibrosis development/progression after sustained virologic response (SVR).
Methods
We performed a retrospective cohort study of 226 consecutive liver transplant recipients with HCV from 2007 to 2018. The cohort was split into transplants pre (Group A) and post (Group B) 2014 to reflect the introduction of DAAs. Fibrosis was monitored with liver biopsy and non‐invasive imaging.
Results
Group B had significantly improved HCV treatment rates and earlier SVR compared to Group A, with a cumulative incidence rate of SVR at 2 years of 86.7% versus 15.4% (HR = .11, p < .001). Prior to achieving SVR, Group A demonstrated worsening of fibrosis stage per year (+.21, p < .001) whereas Group B showed minimal change on protocol annual biopsy (−.02, p = .80). After SVR, most patients were followed non‐invasively and demonstrated stable or improved fibrosis stage over time. Patients undergoing transient elastography showed regression in fibrosis stage per year (−.19, p < .001).
Conclusion
HCV patients undergoing LT after 2014 had higher rates of SVR and improved clinically relevant transplant outcomes, namely less graft loss and death relating to HCV. Fibrosis progression halted or improved after SVR in both cohorts, suggesting that LT recipients with SVR do not require fibrosis monitoring even with established fibrosis prior to SVR.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Division of Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA.
- Division of Internal Medicine, St. Agnes Hospital, Baltimore, Maryland, USA.
- Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA.
- Division of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, Minnesota, USA.
- Division of Digestive Care and Endoscopy, Dalhousie University, Halifax, Nova Scotia, Canada.
ORCID profiles: Alex Liu, Tasha Kulai
Cite
APA
Liu, A., Angirekula, M., Elhawary, A., Mara, K., Kulai, T., Leise, M., & Watt, K. D. (2023). Progression of fibrosis in liver transplant recipients with hepatitis C before and after sustained virologic response. Clinical Transplantation. https://doi.org/10.1111/ctr.15050
Vancouver
Liu A, Angirekula M, Elhawary A, Mara K, Kulai T, Leise M, et al. Progression of fibrosis in liver transplant recipients with hepatitis C before and after sustained virologic response. Clinical Transplantation. 2023. doi:10.1111/ctr.15050
BibTeX
@article{Liu2023,
author = {Liu, Alex and Angirekula, Mounika and Elhawary, Ahmed and Mara, Kristin and Kulai, Tasha and Leise, Michael and Watt, Kymberly D},
title = {Progression of fibrosis in liver transplant recipients with hepatitis C before and after sustained virologic response},
journal = {Clinical Transplantation},
year = {2023},
doi = {10.1111/ctr.15050}
}
EUVIMED